Clinical trials of adenoviruses in brain tumors: A review of Ad-p53 and oncolytic adenoviruses

Giacomo G. Vecil; Frederick F. Lang

doi:10.1023/B:NEON.0000003653.45635.32

Clinical trials of adenoviruses in brain tumors: A review of Ad-p53 and oncolytic adenoviruses

Giacomo G. Vecil, Frederick F. Lang

Neurosurgery

Research output: Contribution to journal › Review article › peer-review

79 Scopus citations

Abstract

Adenoviruses have been critical in the development of the molecular approaches to brain tumors. They have been engineered to function as vectors for delivering therapeutic genes in gene therapy strategies, and as direct cytotoxic agents in oncolytic viral therapies. This review outlines the uses of adenoviruses in brain tumor therapy by examining clinical trials of adenovirus-mediated p53 gene therapy and by reviewing the application of two conditionally replicative adenoviruses (CRAds) ONYX-015 and Delta 24 in brain tumors. The potential clinical use of CRAds that deliver trangenes, particularly p53, is also discussed.

Original language	English (US)
Pages (from-to)	237-246
Number of pages	10
Journal	Journal of neuro-oncology
Volume	65
Issue number	3
DOIs	https://doi.org/10.1023/B:NEON.0000003653.45635.32
State	Published - Dec 2003

Keywords

Adenovirus
Delta-24
Gene therapy
Glioblastoma
ONYX-015
P53

ASJC Scopus subject areas

Oncology
Neurology
Clinical Neurology
Cancer Research

Access to Document

10.1023/B:NEON.0000003653.45635.32

Cite this

@article{bccc17f9fd974a20b0c410d09aad5f1f,

title = "Clinical trials of adenoviruses in brain tumors: A review of Ad-p53 and oncolytic adenoviruses",

abstract = "Adenoviruses have been critical in the development of the molecular approaches to brain tumors. They have been engineered to function as vectors for delivering therapeutic genes in gene therapy strategies, and as direct cytotoxic agents in oncolytic viral therapies. This review outlines the uses of adenoviruses in brain tumor therapy by examining clinical trials of adenovirus-mediated p53 gene therapy and by reviewing the application of two conditionally replicative adenoviruses (CRAds) ONYX-015 and Delta 24 in brain tumors. The potential clinical use of CRAds that deliver trangenes, particularly p53, is also discussed.",

keywords = "Adenovirus, Delta-24, Gene therapy, Glioblastoma, ONYX-015, P53",

author = "Vecil, {Giacomo G.} and Lang, {Frederick F.}",

note = "Funding Information: This project was supported by generous donations of the Brian McCulloch Memorial Fund and the Anthony Bullock III Fund. We thank Dr. Juan Fueyo for his careful critique of the manuscript. We also thank Ian Suk for his assistance with the figure and Sandra Flores for her help with preparation of the manuscript.",

year = "2003",

month = dec,

doi = "10.1023/B:NEON.0000003653.45635.32",

language = "English (US)",

volume = "65",

pages = "237--246",

journal = "Journal of neuro-oncology",

issn = "0167-594X",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - Clinical trials of adenoviruses in brain tumors

T2 - A review of Ad-p53 and oncolytic adenoviruses

AU - Vecil, Giacomo G.

AU - Lang, Frederick F.

N1 - Funding Information: This project was supported by generous donations of the Brian McCulloch Memorial Fund and the Anthony Bullock III Fund. We thank Dr. Juan Fueyo for his careful critique of the manuscript. We also thank Ian Suk for his assistance with the figure and Sandra Flores for her help with preparation of the manuscript.

PY - 2003/12

Y1 - 2003/12

N2 - Adenoviruses have been critical in the development of the molecular approaches to brain tumors. They have been engineered to function as vectors for delivering therapeutic genes in gene therapy strategies, and as direct cytotoxic agents in oncolytic viral therapies. This review outlines the uses of adenoviruses in brain tumor therapy by examining clinical trials of adenovirus-mediated p53 gene therapy and by reviewing the application of two conditionally replicative adenoviruses (CRAds) ONYX-015 and Delta 24 in brain tumors. The potential clinical use of CRAds that deliver trangenes, particularly p53, is also discussed.

AB - Adenoviruses have been critical in the development of the molecular approaches to brain tumors. They have been engineered to function as vectors for delivering therapeutic genes in gene therapy strategies, and as direct cytotoxic agents in oncolytic viral therapies. This review outlines the uses of adenoviruses in brain tumor therapy by examining clinical trials of adenovirus-mediated p53 gene therapy and by reviewing the application of two conditionally replicative adenoviruses (CRAds) ONYX-015 and Delta 24 in brain tumors. The potential clinical use of CRAds that deliver trangenes, particularly p53, is also discussed.

KW - Adenovirus

KW - Delta-24

KW - Gene therapy

KW - Glioblastoma

KW - ONYX-015

KW - P53

UR - http://www.scopus.com/inward/record.url?scp=0347504489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347504489&partnerID=8YFLogxK

U2 - 10.1023/B:NEON.0000003653.45635.32

DO - 10.1023/B:NEON.0000003653.45635.32

M3 - Review article

C2 - 14682374

AN - SCOPUS:0347504489

SN - 0167-594X

VL - 65

SP - 237

EP - 246

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

IS - 3

ER -

Clinical trials of adenoviruses in brain tumors: A review of Ad-p53 and oncolytic adenoviruses

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this